BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
Key Highlights
- ➤BridgeBio will present 10 acoramidis studies at HFSA Annual Scientific Meeting 2026
- ➤Comparative real-world EHR study will evaluate acoramidis versus tafamidis in ATTR-CM
- ➤Acoramidis is approved as Attruby in the United States for ATTR-CM
- ➤Acoramidis targets cardiovascular death and cardiovascular-related hospitalization reduction in adults
- ➤Attruby diarrhea occurred in 11.6% versus 7.6% with placebo
Expert Statements
David Lanfear, Chief Scientific Officer of Henry Ford Health
“Real-World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform”
Ahmad Masri, M.D., M.S., Oregon Health & Science University
“Early eGFR Dip Following Acoramidis Initiation is Associated with Reduced Risk of Mortality and Recurrent Cardiovascular-Related Hospitalizations in ATTR-CM”
James L. Januzzi, M.D., Massachusetts General Hospital
“Ratio of Serum Transthyretin to NT-proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM”
Quan Bui, M.D., UC San Diego Health
“Association Between the Burden of Cardiovascular-Related Hospitalizations and All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM”
Nitasha Sarswat, M.D., University of Chicago
“Falls and Fractures Drive Increased Hospitalizations and Costs in Patients with Transthyretin Amyloid Cardiomyopathy Compared with Controls”
Richard Wright, M.D., Pacific Heart Institute
“Real-World Burden of Transthyretin Amyloid Cardiomyopathy Disease and Outcomes in Patients on Tafamidis Prior to Initiating Acoramidis”
Margot Davis, M.D., University of British Columbia
“Acoramidis Reduces Risk of Cardiovascular-Related Mortality and Hospitalization in Women with Transthyretin Amyloid Cardiomyopathy”
Lily Stern, M.D., Cedars-Sinai Heart Institute
“Acoramidis Preserves Functional Capacity and Quality of Life in p.Val142Ile Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM”
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one oral presentation, three rapid-fire oral presentations, and six poster presentations on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026, taking place in Phoenix, Arizona on October 9-12, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
Acoramidis is approved as Attruby(®) by the U.S. FDA and is approved as BEYONTTRA(®) by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.
Get started
Create a free account to read the full story.